Background {#Sec1}
==========

Tracheostomy is generally performed in neurosurgical patients and may be performed more vigilantly in cases of brain injuries \[[@CR1]\]. Several critical conditions should be considered such as intracranial hypertension, changed cerebral perfusion, and abnormal cerebral autoregulation if tracheostomy is performed in neurosurgical patients and neurocritically ill patients \[[@CR1]\]. In such patients, procedural pain and anxiety may induce neurologically adverse events such as increased brain metabolism and intracranial hypertension \[[@CR2]--[@CR4]\]. Therefore, it is necessary to adequately control procedural pain and anxiety during the procedure in these patients.

Percutaneous dilatational tracheostomy (PDT) has been increasingly used because of easy placement and lower rates of clinically significant bleeding and wound infection \[[@CR1], [@CR5]\]. In addtion, a neurointensivist is specialist with a focus on the management of brain-injured patients with neurosurgical problems \[[@CR6]\]. Therefore, PDT performed by a neurointensivist may have many theoretical advantages due to easy placement at the bedside, low risk of complications, and specialized management of brain-injured patients \[[@CR1], [@CR5]\]. In PDT performed by a neurointensivist, procedure induced severe pain-related adverse events (SAE) may be reduced. The purpose of this study was to investigate the SAE of PDT performed by a neurointensivist compared with conventional surgical tracheostomy in neurosurgical patients and neurocritcally ill patients.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This was a retrospective, single-center, and observational study of adult patients admitted to the neurosurgical intensive care unit (ICU) at Samsung Medical Center between January 2014 and March 2018. This study was approved by the Institutional Review Board of Samsung Medical Center (SMC 2018--09-011). The requirement for informed consent was waived due to its retrospective nature. Clinical and laboratory data were collected by a trained study coordinator using a standardized case report form. We included adult patients admitted to the neurosurgical ICU who underwent tracheostomy during the study. The patient list was cross-referenced with the electronic order entry system and the electronic medical records to identify the patients who underwent tracheostomy during their ICU stay. Those hospitalized for more than 14 days after tracheostomy were selected. Of these patients, we excluded patients under 18 years of age, those without brain injury, and those with insufficient medical records. In addition, patients were excluded if they were admitted to departments other than neurosurgery (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Study flow chart. ICU, intensive care unit; PDT, percutaneous dilatational tracheostomy

Definitions and outcomes {#Sec4}
------------------------

We retrospectively reviewed all neurosurgical patients and neurocritcally ill patients who underwent tracheostomy and were admitted to the neurosurgical ICU during the study. All patients underwent a preliminary chart review to ensure that a T-cannula had been placed. The following baseline demographics were abstracted from the electronic medical chart including patient's age and comorbidities, causes of ICU admission, severity scores on ICU admission, indication for tracheostomy, laboratory data on tracheostomy, vital signs monitored during the procedure, duration of the dwell time for the device, and causes of removal. As associated data of the tracheostomy procedure, we investigated the initial success of tracheostomy and procedure time. Procedure time was defined as the time from sterilization to the connection of the tracheostomy tube with the mechanical ventilator after successful tracheostomy \[[@CR7], [@CR8]\]. Primary endpoints were incidences of SAE: cardiac arrest, arrhythmias including tachycardia and bradycardia, hypertension, hypotension, desaturation, bradypnea, or ventilatory distress \[[@CR9]\]. In this study, the incidence of SAE was mainly focused on brand new adverse events. SAE were retrospectively assessed by reviewing the medical records. SAE related to acute stress response were assessed based on physiological parameters (cardiac rhythm, heart rate, mean arterial pressure, respiratory rate, and oximetry) and measured continuously by the ICU monitor and recorded before and while the procedure by the bedside nurse on a sheet dedicated to the study. Tachycardia: heart rate ≥ 110 beats/minute (b/min) if \< 100 b/min before the procedure; Bradycardia: heart rate ≤ 60 b/min if \> 70 b/min before; Hypertension: mean arterial pressure ≥ 110 mmHg if \< 100 mmHg before; Hypotension: mean arterial pressure ≤ 65 mmHg if \> 70 mmHg before; Desaturation: oxygen saturation ≤ 90% if \> 92% before; Bradypnea: respiratory rate ≤ 10 breaths/minutes (B/min) if \> 10 B/min before; Ventilatory distress: severe ventilator asynchrony (non-stop coughing or impossible ventilation) in mechanically ventilated patients and/or tachypnea (respiratory rate ≥ 35 B/min if it was \< 35 B/min) \[[@CR9]\]. The secondary endpoint was defined as procedure-induced complications. We investigated complications at insertion or during maintenance such as insertional injury, bleeding or hematoma, fracture of the tracheal ring, cuff perforation, accidental decannulation, surgical conversion, hypoxemia, stomal ulcer, wound infection, and ventilator-associated pneumonia (VAP). As associated post-procedural bleeding complications, minor bleeding was defined as bleeding from the incision site that required dressing more than three times a day or epinephrine for local homeostasis. Major bleeding was defined as bleeding that required cauterization, surgical treatment, or additional blood transfusion \[[@CR7], [@CR8]\]. Arrhythmia developed during the procedure included bradycardia, sinus tachycardia, supraventricular tachycardia, arterial fibrillation, ventricular tachycardia, and ventricular fibrillation \[[@CR7]\]. VAP was defined if patients received clinical diagnosis more than 48 h after tracheotomy, received antimicrobial therapy, and had a new radiographical infiltrate and two of three clinical criteria: purulent secretions, fever, and leukocytosis or leukopenia \[[@CR1], [@CR10]\]. VAP was also identified by cross-referencing with VAP monitoring of the Infection Prevention and Control Team at Samsung Medical Center. In this study, early and late-onset VAPs were defined as the occurrence of the events on four days or less and greater than four days after tracheostomy \[[@CR11]\]. We defined initial success when the procedure was successfully performed at the first trial. The stroke-related early tracheostomy score (SETscore) was used to assess the need for tracheostomy and its external validation \[[@CR12], [@CR13]\]. In this study, a neurointensivist co-management was initiated in October 2014 \[[@CR6]\]. A neurointensivist or neurosurgeon determined tracheostomy. Procedure of tracheostomy was performed in the same way as our previous study \[[@CR5]\]. In PDT performed by a neurointensivist, patients received sedation and pain control with propofol or midazolam, intravenous analgesics with fentanyl and/or remifentanil, and topical analgesic with 1.5% lidocaine and 1:200,000 epinephrine \[[@CR1], [@CR5]\]. Especially, at least 30 min before the procedure, a continuously high dose infusion of propofol and bolus administration of osmotic agent were performed in patients with intracranial hypertension. Before the administration of the neuromuscular blockade, the goal of sedation was to achieve the Richmond Agitation Sedation Scale goal of negative 4 to 5 \[[@CR5], [@CR14], [@CR15]\]. In tracheostomy performed by a neurointensivist and neurosurgeon, the first tracheostomy tube change was performed seven days after placement. However, it was performed three days after placement in conventional tracheostomy performed by an otolaryngologist \[[@CR5]\].

Statistical analyses {#Sec5}
--------------------

All data are presented as means ± standard deviations for continuous variables and numbers (percentages) for categorical variables. Data were compared using Student's *t*-test for continuous variables and Chi-square test or Fisher's exact test for categorical variables. Pearson's correlation coefficient (*r*) was calculated to determine the correlation between the variables. To investigate independent and meaningful effects of clinically relevant variables, we considered a multivariable regression model, including variables such as age, sex, body mass index, Glasgow Coma Scale on tracheostomy, PDT by a neurointensivist, and use of sedative or analgesic. We used a multivariable linear model for the outcome of the duration of SAE and a multivariable logistic model for the outcome of the incidence of SAE. In the case of multivariable adjustment for the incidence of SAE, we paid extra attention to ensure adequate power of the analysis without overfitting and multicollinearity. All tests were two-sided and *P* values \< 0.05 were considered as statistically significant. Data were analyzed using IBM SPSS statistics version 20 (IBM, Armonk, NY, USA).

Results {#Sec6}
=======

Baseline characteristics and procedural characteristics {#Sec7}
-------------------------------------------------------

A total of 156 patients (74 males; 47.4%) were analyzed in this study. Among these patients, 71 patients underwent PDT by a neurointensivist and 85 patients underwent conventional tracheostomy (61 by neurosurgeons and 24 by otolaryngologists) during the study period. Conventional tracheostomy was performed in eight (5.1%) patients in the operating room. The mean age of the patients was 59.6 ± 14.3 years. Hypertension (57.7%) and diabetes mellitus (28.8%) were the most common comorbidities among patients who underwent tracheostomy. Elective brain tumor surgery (34.0%) and intracranial hemorrhage (20.5%) were the most common reasons for ICU admission. There were no significant differences in age, gender, body mass index, comorbidities, and APACHE II score on ICU admission between the two groups except for the reason for admission and the Glasgow Coma Scale (Table [1](#Tab1){ref-type="table"}). Difficult ventilator weaning or prolonged intubation (42.9%) and sedative reduction (23.7%) were the most common reasons for tracheostomy. Midazolam (70.3%) was most commonly used among sedatives and analgesics. There were no significant differences in laboratory results of coagulation on the day of tracheostomy between the two groups (Table [2](#Tab2){ref-type="table"}). Table 1Baseline characteristicsPDT performed by a neurointensivist (*n* = 71)Conventional surgical method (*n* = 85)*P* valueAge (yr) --- mean ± SD58.1 ± 15.560.8 ± 13.20.245Gender, male --- No. of patients (%)35 (49.3)39 (45.9)0.671BMI (kg/m^2^) --- mean ± SD23.7 ± 3.723.8 ± 4.00.815Obese (BMI \> 30 kg/m^2^) --- No. of patients (%)4 (5.6)5 (5.9)0.999Comorbidities --- No. of patients (%) Hypertension38 (53.5)52 (61.2)0.335 Diabetes mellitus23 (32.4)22 (25.9)0.371 Malignancy23 (32.4)13 (15.3)0.012 Dyslipidemia13 (18.3)22 (25.9)0.259 Chronic kidney disease5 (7.0)6 (7.1)0.997 Coronary artery disease4 (5.6)5 (5.9)0.999 Chronic liver disease3 (4.2)4 (4.7)0.999Reason for ICU admission --- No. of patients (%)0.012 Brain tumor34 (47.9)19 (22.4) Intracranial hemorrhage10 (14.1)22 (25.9) Traumatic brain injury12 (16.9)19 (22.4) Subarachnoid hemorrhage8 (11.3)20 (23.5) Cerebral infarction2 (2.8)4 (4.7) CNS infection1 (1.4)1 (1.2) Other4 (5.6)1 (1.2)GCS on ICU admission --- mean ± SD7.7 ± 4.06.2 ± 2.70.008APACHE II score on ICU admission --- mean ± SD26.0 ± 5.127.4 ± 4.30.050*PDT* Percutaneous dilatational tracheostomy, *SD* standard deviation, *BMI* body mass index, *TIA* transient ischemic attack, *ICU* intensive care unit, *CNS* central nerve system, *GCS* Glasgow Coma Scale, *APACHE* Acute Physiology and Chronic Health EvaluationTable 2Procedural characteristics at the time of tracheostomyPDT performed by a neurointensivist (*n* = 71)Conventional surgical method (*n* = 85)*P* valueReason for tracheostomy --- No. of patients (%)0.853 Difficult ventilator weaning or prolonged intubation33 (46.5)34 (40.0) Reduction of sedative15 (21.1)22 (25.9) Airway protection or prevent the risk of aspiration15 (21.1)21 (24.7) Airway toilet5 (7.0)4 (4.7) Difficult airway3 (4.2)4 (4.7)Premedication --- No. of patients (%) Midazolam44 (62.0)65 (76.5)0.049 Cisatracurium59 (83.1)2 (2.4)\< 0.001 Fentanyl55 (77.5)2 (2.4)\< 0.001 Pethidine15 (21.1)29 (34.1)0.106 Propofol15 (21.1)2 (2.4)0.001 Vecuronium11 (15.5)2 (2.4)0.008 Remifentanil7 (9.9)4 (4.7)0.348 Succinylcholine3 (4.2)16 (18.8)0.011 Other5 (7.0)8 (9.4)0.808Anticoagulation --- No. of patients (%)0 (0.0)1 (1.2)0.999Use of antiplatelet agent --- No. of patients (%)5 (7.0)1 (1.2)0.093GCS on procedure --- mean ± SD8.6 ± 3.78.3 ± 3.50.653Use of renal replacement therapy --- No. of patients (%)3 (4.2)3 (3.5)0.999Invasive ICP monitoring --- No. of patients (%)20 (28.2)25 (29.4)0.865Duration of mechanical ventilation before tracheostomy (days) --- mean ± SD8.9 ± 5.88.2 ± 5.80.406Inserted site --- No. of patients (%)0.045 1st tracheal membrane16 (22.5)35 (41.2) 2nd tracheal membrane39 (54.9)34 (40.0) 3rd tracheal membrane16 (22.5)16 (18.8)Internal diameter of T-cannula (mm) --- No. of patients (%)\< 0.001 6.00 (0)1 (1.2) 7.01 (1.4)22 (25.9) 7.535 (49.3)35 (41.2) 8.033 (46.5)24 (28.2) Adjustable flange2 (2.8)3 (3.5)Lab results on the day of tracheostomy --- mean ± SD Platelet count (× 10^3^/μl)252.2 ± 111.6266.1 ± 107.00.440 PT (INR)1.0 ± 0.21.0 ± 0.10.461 aPTT (sec)38.9 ± 9.537.6 ± 6.40.330Ventilator setting --- mean ± SD FiO~2~ (%)39.9 ± 18.636.0 ± 7.00.094 PEEP (cmH~2~O)5.1 ± 0.84.9 ± 1.80.315Vasopressor requirement --- No. of patients (%)11 (15.5)13 (15.3)0.973*PDT* Percutaneous dilatational tracheostomy, *SD* standard deviation, *ICP* intracranial pressure, *INR* international normalized ratio, *aPTT* activated partial thromboplastin time, *FiO*~*2*~ Fraction of inspired oxygen, *PEEP* positive end-expiratory pressure

Clinical outcomes {#Sec8}
-----------------

Arrhythmia (30.4%) and hypertension (30.1%) were the most common events of SAE. Incidence of SAE was more common in patients who underwent conventional tracheostomy compared to patients who underwent PDT (67.1% vs. 42.3%, *P* = 0.002, Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). The total duration of SAE was longer in patients who underwent conventional tracheostomy compared to patients who underwent PDT (19.8 ± 23.0 min vs. 3.4 ± 5.3 min, *P* \< 0.001). In conventional tracheostomy, procedural time (42.2 ± 21.8 min vs. 17.7 ± 9.2 min, *P* \< 0.001) was longer and analgesics were less used compared to PDT (38.8% vs. 84.5%, *P* \< 0.001) (Table [2](#Tab2){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). However, there was no difference in the use of sedatives between the two groups (81.2% vs. 73.2%, *P* = 0.237). Multivariable logistic regression analysis revealed that only PDT performed by a neurointensivist significantly reduced the incidence of SAE by one third (adjusted odds ratio \[OR\]: 0.36, 95% confidence interval \[CI\]: 0.187--0.691). Also, the duration of SAE was significantly different in cases of PDT performed by intensivists and surgeons. The SAE duration of PDT performed by neurointensivist (3.4 ± 5.3 min) was shortest compared with that of tracheostomy performed by an otolaryngologist (13.6 ± 16.7 min) and neurosurgeon (22.2 ± 24.7 min) (*P* \< 0.001). Multivariable adjustment revealed that PDT by a neurointensivist exhibited a decrease in the duration of SAE by 8.64 min (β: -8.64, 95% CI: -15.070 -- -2.205, *P* = 0.009) and prolonging the procedure time by every one minute significantly increased the duration of SAE by 6.38 min (β: 6.38, 95% CI: 0.166--0.470, *P* \< 0.001). Procedure-induced complications were more common in patients who underwent conventional tracheostomy compared to patients who underwent PDT (23.5% vs. 11.3%, *P* = 0.047, Fig. [4](#Fig4){ref-type="fig"}). Although moderate or major bleeding occurred in six patients who underwent a conventional tracheostomy, only one patient had moderate bleeding in PDT. Especially, there were two respiratory arrests during conventional tracheostomy. Additionally, two early-onset VAPs and seven wound infections occurred in cases of conventional tracheostomy. However, there were no significant differences in mortalities and length of stay in the ICU and hospital between the two groups. Table 3Clinical outcomesPDT performed by a neurointensivist (*n* = 71)Conventional surgical method (*n* = 85)*P* valueIncidence of SAE --- No. of patients (%)30 (42.3)57 (67.1)0.002Event of SAE --- No. of events (%) Arrhythmia13 (18.3)36 (42.4)0.001  Tachycardia13 (18.3)34 (40.0)  Bradycardia0 (0)3 (3.5) Hypertension13 (18.3)34 (40.0)0.003  Use of the antihypertensive drug during the procedure7 (9.9)11 (12.9)0.728 Ventilator distress0 (0)10 (11.8)0.008 Hypotension1 (1.4)5 (5.9)0.303 Desaturation0 (0)4 (4.7)0.179 Arrest0 (0)2 (2.4)0.558 Bradypnea0 (0)1 (1.2)0.999 Use of hyperosmolar agent during procedure0 (0)3 (3.5)0.311Duration of total SAE (min) --- mean ± SD3.4 ± 5.319.8 ± 23.0\< 0.001Procedural data Initial success of tracheostomy --- No. of patients (%)71 (100)81 (95.3)0.179 Procedure time (min) --- mean ± SD17.7 ± 9.242.2 ± 21.8\< 0.001Outcomes ICU mortality --- No. of patients (%)2 (2.8)1 (1.2)0.187 Hospital mortality --- No. of patients (%)6 (8.5)9 (10.6)0.651 Length of stay in ICU (days) --- mean ± SD17.35 ± 13.218.11 ± 18.40.773 Length of stay in hospital (days) --- mean ± SD78.74 ± 117.179.06 ± 136.20.988*SAE* severe pain-related adverse events, *PDT* Percutaneous dilatational tracheostomy, *SD* standard deviation, *ICU* intensive care unitFig. 2Incidence of severe pain-related adverse events (SAE). PDT, percutaneous dilatational tracheostomyFig. 3Procedural times (**a**) and severe pain-related adverse events (SAE) according to sedative and analgesic administration (**b**) between the two groups. PDT, percutaneous dilatational tracheostomyFig. 4Procedure-induced complications. PDT, percutaneous dilatational tracheostomy; VAP, ventilator-associated pneumonia

In this study, the implementation of PDT was progressively increased compared to conventional tracheostomy (Fig. [5](#Fig5){ref-type="fig"}a). Especially, the total number of tracheostomy rapidly increased from the fourth quarter of 2015. There were no significant differences in the SETscore between the PDT group and the conventional tracheostomy group (15.9 ± 5.6 vs. 16.6 ± 5.3, *P* = 0.478). However, the SETscore before the fourth quarter of 2015 was significantly higher compared with that after the fourth quarter of 2015 (18.6 ± 5.0 vs. 14.6 ± 4.8, *P* \< 0.001). Based on a simple correlation analysis, we found a linear trend with moderate to high correlation for the number of PDT, conventional surgical tracheostomy, and total tracheostomy (*r* = 0.915, *P* \< 0.001, *r* = − 0.544, *P* = 0.024 and *r* = 0.667, *P* = 0.003, respectively). Besides, the overall incidence rate of SAE exhibited a gradual decrease (Fig. [5](#Fig5){ref-type="fig"}b). A linear trend with high correlation for the incidence rate of SAE was observed (*r* = − 0.655, *P* = 0.004). Fig. 5The number of total tracheostomy and PDT increased progressively compared to conventional tracheostomy (**a**). Especially, the total number of tracheostomy rapidly increased from the fourth quarter of 2015. Based on a simple correlation analysis, we found a linear trend with moderate to high correlation for the numbers of PDT, conventional surgical tracheostomy, and total tracheostomy (*r* = 0.915, *P* \< 0.001, *r* = − 0.544, *P* = 0.024 and *r* = 0.667, *P* = 0.003, respectively). The overall incidence rate of SAE was gradually decreased (**b**). The incidence rate of SAE was calculated as the percentage of the number of SAE over the number of tracheostomies. We found a linear trend with high correlation for the incidence rate of SAE (*r* = − 0.655, *P* = 0.004)

Based on simple correlation analysis, the timing of tracheostomy showed a linear correlation with the length of ICU stay (*r* = 0.505, *P* \< 0.001). However, the timing of tracheostomy was not significantly different between ICU survivors and non-survivors (9.3 ± 6.8 days vs. 13.2 ± 7.5 days, *P* = 0.328).

Discussion {#Sec9}
==========

In this retrospective and exploratory study involving our single-center limited cohort of tracheostomy patients, we investigated the SAE of PDT performed by a neurointensivist at bedside compared with conventional surgical tracheostomy in neurosurgical patients. The major findings of this study are as follow: 1) After initiated neurointensivist co-management, the overall incidence rate of SAE was gradually decreased. Especially, incidence and duration of SAE were lower in patients who underwent PDT performed by a neurointensivist rather than in the case of patients who underwent conventional tracheostomy. Also, procedural time was longer in the conventional surgical tracheostomy group compared to the PDT group; 2) In multivariable analysis, the duration of SAE was associated with procedure time and operator. Incidence of SAE was only associated with PDT performed by a neurointensivist; 3) Procedure-induced complications were more common in patients who underwent conventional tracheostomy; and 4) In this study, implementation of total tracheostomy and PDT exhibited a progressive increase. However, the number of conventional surgical tracheostomy decreased gradually.

Pain is associated with acute stress response including changes in heart rate, blood pressure, respiratory rate, neuroendocrine secretion, and psychological distress such as agitation \[[@CR9]\]. In neurocritically ill patients, including procedural pain, pain can increase cerebral metabolic demand which further increases intracranial pressure (ICP) \[[@CR2]--[@CR4]\]. Increased ICP can cause secondary brain ischemia due to decreased cerebral perfusion and blood flow, brain tissue hypoxia, metabolic crisis, and even result in herniation \[[@CR16]\]. In addition, anxiety can increase cerebral metabolic demand which might further increase cerebral blood flow and ICP \[[@CR2]\]. Sedation and analgesia are often required in the case of neurocritically ill patients with severe brain edema; both can also be used to manage ICP and cerebral perfusion pressure and attenuate stress response, increase endotracheal tube tolerance, reduce cerebral metabolic demand, prevent delirium, and decrease ventilator synchrony \[[@CR16]\]. Therefore, appropriate levels of sedation and analgesia are necessary to control procedural pain and anxiety during tracheostomy in neurocritically ill patients.

In this study, neurointensivist co-management was initiated in October 2014. After initiated neurointensivist co-management, the overall incidence rate of SAE demonstrated a gradual decrease. There are several reasons behind the development of PDT as an appropriate skill for neurointensivists \[[@CR1]\]. Neurointensivists are specialists with a focus on the management of patients with acute neurologic conditions including traumatic brain injury, stroke, status epilepticus, hypoxic-ischemic encephalopathy, and neuromuscular respiratory failure \[[@CR6]\]. Frequency of tracheostomy is high among patients with neurocritically ill problems \[[@CR17]--[@CR22]\]. Neurointensivists need to be more vigilant in recognizing and managing subtle dangers that may occur during the procedure such as hypoventilation, head-down positioning, hypoxia, hypotension, and elevated ICP in case of brain-injured patients \[[@CR20], [@CR23], [@CR24]\]. Herein, during PDT performance by a neurointensivist, continuous propofol infusion and bolus injection of hyperosmolar agents were initiated before the procedure in patients with intracranial hypertension. Therefore, a neurointensivist may have advantages of management and procedure in neurosurgical patients and neurocritically ill patients. Especially, decreased SAE might be associated with the initiation of neurointensivist co-management in this study.

In the current study, the number of total tracheostomy and PDT exhibited a progressive increase. Especially, the total number of tracheostomy cases rapidly increased from the fourth quarter of 2015. The SETscore before the fourth quarter of 2015 was significantly higher compared with that after the fourth quarter of 2015. Therefore, the indication for tracheostomy may be considered to be wider and easier compared with that of the past in patients with acute brain injury. A recent study reported an increase in tracheostomy utilization in the USA among patients with severe acute brain injury \[[@CR25]\]. The increasing trend of tracheostomy has arisen from positive reasons such as easy weaning from the ventilator, facilitation of earlier discharge from intensive care, improved patient safety, etc. \[[@CR25]\]. Also, tracheostomy and its timing have been hypothesized to be associated with clinical outcomes \[[@CR26]\]. In this study, the timing of tracheostomy showed a linear correlation with the length of ICU stay. However, ICU mortality was not associated with the timing of tracheostomy.

This study has several limitations. First, it was a retrospective review of medical records. Especially, SAE were assessed by retrospectively reviewing of medical records. Vital signs and special events during the procedure were evaluated and recorded by the bedside nurses and not by an independent investigator. Therefore, there might be a bias according to each recorder. In addition, there existed a limitation to access the pain response in case a patient had abnormal vital signs before the procedure. Second, tracheostomy was determined by a neurointensivist or neurosurgeon, rather than by protocol-based procedure. Additionally, the non-randomized nature of the registry data may have resulted in selection bias. Third, the neurointensivist in our hospital is a neurologist trained to manage all aspects of critically ill patients in medical and surgical ICUs. The treatment tendency of this neurointensivist might have influenced clinical outcomes in neurosurgical patients. Finally, our study has limited statistical power due to the small sample size. Although numerous comparisons were made, there exists a possibility of the presence of false-positive findings in this study. However, the results still provide valuable insight. Consequently, prospective large-scale studies are needed to evaluate the usefulness of PDT by a neurointensivist for severe brain-injured patients to obtain evidence-based conclusions.

Conclusions {#Sec10}
===========

In this retrospective and exploratory study of our single-center limited cohort of tracheostomy patients, we found that the incidence and duration of SAE were lower in PDT rather than conventional surgical tracheostomy. Decreased SAE may be associated with short procedural time and PDT performed by a neurointensivist. Therefore, it is proposed that PDT performed by a neurointensivist may be safe and feasible in neurocritically ill patients.
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